Increased ubiquitination of EZH2 or ALK for cancer therapies

Papers published in Cell Reports and Journal of Medicinal Chemistry suggest that targeted degradation by increasing ubiquitination of proteins that promote cancer could be a more complete strategy to treat cancer than catalytic inhibition.

As increased expression of enhancer of zeste homolog 2 (EZH2) has been shown to promote multiple types of cancer, EZH2 enzymatic inhibitors have been explored as cancer therapies. However, studies have shown blocking EZH2 enzyme function was insufficient to inhibit proliferation of some cancer cells, suggesting that increased elimination of EZH2 could be more efficacious...